Editas Medicine, Inc. (EDIT)

NASDAQ: EDIT · IEX Real-Time Price · USD
13.47
-0.03 (-0.22%)
At close: Jun 24, 2022 4:00 PM
13.53
+0.06 (0.45%)
After-hours: Jun 24, 2022 5:39 PM EDT
-0.22%
Market Cap 924.60M
Revenue (ttm) 25.82M
Net Income (ttm) -186.29M
Shares Out 68.64M
EPS (ttm) -2.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,183,274
Open 13.77
Previous Close 13.50
Day's Range 12.44 - 13.94
52-Week Range 9.59 - 73.03
Beta 2.06
Analysts Buy
Price Target 32.88 (+144.1%)
Earnings Date Aug 3, 2022

About EDIT

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pi... [Read more...]

Industry Biotechnology
IPO Date Feb 3, 2016
CEO Cynthia Collins
Employees 264
Stock Exchange NASDAQ
Ticker Symbol EDIT
Full Company Profile

Financial Performance

In 2021, EDIT's revenue was $25.54 million, a decrease of -71.85% compared to the previous year's $90.73 million. Losses were -$192.50 million, 66.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 23 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is 32.88, which is an increase of 144.10% from the latest price.

Price Target
$32.88
(144.10% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T ...

TUEBINGEN, Germany and HOUSTON and CAMBRIDGE, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and de...

Editas Medicine Reports Inducement Grants to New Chief Executive Officer

CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company's newly appointe...

Editas (EDIT) Down 20.7% Since Last Earnings Report: Can It Rebound?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

Cathie Wood Is Selling Gene Editing Stocks. Here's Why.

Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?

Other symbols: ARKGBNRIONS

Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annua...

SLEEK results in highly efficient multi-transgene knock-in and enables tunability of transgene expression

Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia

The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.

Why Editas Medicine's Shares Fell 28.9% This Week

The company's progress for its lead therapy has been slow.

Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia

Company on track to dose first transfusion-dependent beta thalassemia patient with EDIT-301 by year-end Company on track to dose first transfusion-dependent beta thalassemia patient with EDIT-301 by yea...

Editas' (EDIT) Q1 Loss Narrows, Revenues Beat Estimates

Editas (EDIT) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates. Focus on lead candidate, EDIT-101.

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentos...

Studies in non-human primates demonstrated nearly 100% gene editing knockout of endogenous RHO gene and more than 30% replacement protein levels

Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of 8.64% and 44.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Editas Medicine Announces First Quarter 2022 Results and Business Updates

Appointed Gilmore O'Neill as CEO effective June 1, 2022; James C. Mullen to serve as Executive Chairman

Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene E...

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that four abstracts have been accepted for presentation, includ...

Editas Medicine (EDIT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Editas (EDIT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday,...

Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia

CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Rare...

3 Ominous Reasons to Avoid This Biotech Pioneer

They point to trouble for investors counting on a rebound.

Other symbols: CRSPNTLA

Editas Medicine Appoints Gilmore O'Neill as Chief Executive Officer

James C. Mullen to Serve as Executive Chairman

Editas (EDIT) Begins Dosing Pediatric Patients in Gene Drug Study

Editas (EDIT) doses the first patient pediatric patient in the BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10).

Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

Marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

Preclinical data demonstrate that edited iNK cells result in increased persistence, enhanced anti-tumor activity and extended survival supporting continued development as a novel therapeutic approach fo...

Thanks To These CRISPR Stocks, The Path To Rewriting Human DNA Is About To Get Pretty Fierce

Experts say CRISPR-based treatments could soon constitute a massive market — and the prospects are grabbing Big Pharma's attention. Investor's Business Daily has been helping people invest smarter resul...

Other symbols: NTLA

Editas (EDIT) Soars 6.3%: Is Further Upside Left in the Stock?

Editas (EDIT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the...

Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents

The U.S. Patent and Trademark Office has ruled in favor of the Broad Institute of MIT and Harvard in a dispute over the patents around CRISPR gene-editing technology. The decision is part of a long-runn...

Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued another fa...